What question did this study set out to answer?

To assess the effectiveness of neoadjuvant zanidatamab combined with chemotherapy in achieving pathologic complete response in HER2+ early breast cancer.

February 22, 2026Clinical Cancer Research

Abstract PS3-11-28: EmpowHER-208: A phase 2 neoadjuvant study of zanidatamab in combination with chemotherapy in patients with stage II-III HER2-positive early breast cancer

View Full Paper

Ask AI

Bookmark

To assess the effectiveness of neoadjuvant zanidatamab combined with chemotherapy in achieving pathologic complete response in HER2+ early breast cancer.
Phase 2, randomized, open-label design
Participants with untreated, stage II-III HER2+ early breast cancer
Randomized 2:2:1 to ZT, ZTC, or TCHP regimens
Treatment includes zanidatamab combined with paclitaxel or docetaxel and carboplatin
Primary endpoint: pathologic complete response rate assessed locally
Planned evaluation of pCR rates with zanidatamab combinations
Key secondary endpoints include response rates and event-free survival
Expected assessment of safety and tolerability profile of the treatments

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase 2 study evaluates neoadjuvant zanidatamab combined with chemotherapy in HER2+ early breast cancer, suggesting improved outcomes.

Cite This Study

Waks et al. (2026) studied this question.

synapsesocial.com/papers/699a9dcd482488d673cd3f69 https://doi.org/10.1158/1557-3265.sabcs25-ps3-11-28

View Full Paper

Ask AI

Bookmark

Abstract PS3-11-28: EmpowHER-208: A phase 2 neoadjuvant study of zanidatamab in combination with chemotherapy in patients with stage II-III HER2-positive early breast cancer

Key Points

Discussion

Implication

Cite This Study

Abstract PS3-11-28: EmpowHER-208: A phase 2 neoadjuvant study of zanidatamab in combination with chemotherapy in patients with stage II-III HER2-positive early breast cancer

Key Points

Discussion

Implication

Cite This Study